IQVIA Holdings (NYSE:IQV) has seen varied performance in recent years, with investors experiencing a 67% increase over the past five years. Various asset management firms are adjusting their positions in the biotech company: TD Asset Management dramatically sold 106,743 shares while US Bancorp DE increased their stock position, signalling a range of confidence in the company's future. The company's stock has consistently underperformed compared to competitors, however, analysts suggest retaining the stock for now. Despite a 31.8% drop since the last earnings report, Quest Partners LLC and Otter Creek Advisors LLC are increasing their holdings, while others, like Brown Advisory Inc., are reducing their positions. IQV's first quarter of 2024 surpassed revenue estimations and year-over-year growth was substantial in Q4 2023, suggesting a strong future value. Despite insider selling, which ordinarily can indicate a lack of confidence in future performance, financial forecasts estimate Q2 2024 earnings at $2.39 per share. Consistently, IQVIA Holdings Inc. is recognized for sensible use of debt in their financial strategy.
Iqvia Holdings IQV News Analytics from Mon, 04 Oct 2021 07:00:00 GMT to Sun, 02 Jun 2024 14:32:43 GMT -
Rating 2
- Innovation -3
- Information 5
- Rumor -2
